Genmab AS

Genmab AS Short-term Debt

The Short-Term Debt of Genmab AS (GMAB) as of Nov 22, 2026 is 291.00 M USD. In the previous year, Short-Term Debt was 92.00 M USD — a change of 216.30% (higher).

Short-term Debt

291.00 MUSD

YoY

216.30%

Last updated:

Short-Term Debt of Genmab AS is 2025 291.00 M USD. Short-Term Debt of Genmab AS was 2024 92.00 M USD. It decreases by 216.30% higher compared to the previous year.

The Genmab AS Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2018
0.00 USD
Jan 1, 2019
26.00 M USD
Jan 1, 2020
42.00 M USD
Jan 1, 2021
62.00 M USD
Jan 1, 2022
74.00 M USD
Jan 1, 2023
90.00 M USD
Jan 1, 2024
92.00 M USD
Jan 1, 2025
291.00 M USD
The Genmab AS Short-term Debt history
YEARShort-term DebtYoY
291.00 MUSD+216.30%
92.00 MUSD+2.22%
90.00 MUSD+21.62%
74.00 MUSD+19.35%
62.00 MUSD+47.62%
42.00 MUSD+61.54%
26.00 MUSD—
0.00USD—
0.00USD-100.00%
61.61 MUSD+52,113.56%
118,000.00USD-50.21%
237,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genmab AS Stock analysis

What does Genmab AS do? Genmab AS is a biotechnology company based in Copenhagen, Denmark, operating in the Health Care sector. It develops and markets antibody-based therapies for cancer and other diseases, including EPKINLY, TEPKINLY, and Tivdak for various lymphomas and cervical cancer. The company also advances several product candidates in clinical development, such as Epcoritamab for lymphomas and GEN1059 for solid tumors, alongside established treatments like DARZALEX and TECVAYLI for multiple myeloma and other conditions. Genmab AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab AS stock

Short-Term Debt of Genmab AS is 291.00 M USD in 2025.

Short-Term Debt of Genmab AS changed from 92.00 M USD to 291.00 M USD, representing a 216.30% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Short-Term Debt Genmab AS since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's Genmab AS historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Genmab AS

All Key Metrics — Genmab AS